KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Total Liabilities: 2017-2024

Historic Total Liabilities for Aquestive Therapeutics (AQST) over the last 8 years, with Dec 2024 value amounting to $161.6 million.

  • Aquestive Therapeutics' Total Liabilities rose 7.91% to $167.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $167.7 million, marking a year-over-year increase of 7.91%. This contributed to the annual value of $161.6 million for FY2024, which is 1.42% down from last year.
  • According to the latest figures from FY2024, Aquestive Therapeutics' Total Liabilities is $161.6 million, which was down 1.42% from $163.9 million recorded in FY2023.
  • Over the past 5 years, Aquestive Therapeutics' Total Liabilities peaked at $175.6 million during FY2022, and registered a low of $111.4 million during FY2020.
  • Moreover, its 3-year median value for Total Liabilities was $163.9 million (2023), whereas its average is $167.0 million.
  • In the last 5 years, Aquestive Therapeutics' Total Liabilities soared by 31.65% in 2020 and then declined by 6.67% in 2023.
  • Aquestive Therapeutics' Total Liabilities (Yearly) stood at $111.4 million in 2020, then rose by 29.40% to $144.1 million in 2021, then grew by 21.85% to $175.6 million in 2022, then declined by 6.67% to $163.9 million in 2023, then dropped by 1.42% to $161.6 million in 2024.